ArticleJCI insight2017
Plasminogen promotes cholesterol efflux by the ABCA1 pathway.
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 42 citations in OpenAlex.
- Plasma-Based Proteomics Profiling of Patients with Hyperthyroidism after Antithyroid Treatment.Molecules (Basel, Switzerland) · 2020Trial
- Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.Journal of clinical lipidologyTrial
- Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.Journal of clinical lipidologyTrial
- High-Density Lipoprotein-Specific Phospholipid Efflux (HDL-SPE) Assay in Mice.Molecular nutrition & food research · 2026Article
- Ferulic Acid Attenuates Heat Stress-Induced Hepatic and Intestinal Oxidative Stress and Cholesterol Metabolism Dysregulation in Juvenile Blunt Snout Bream (International journal of molecular sciences · 2026Article
- Plasminogen as a ribonucleoprotein: regulatory small RNA cargo modulates fibrinolysis and inflammation.Blood · 2025Article
- Reduced high-density lipoprotein antioxidant function in patients with coronary artery disease and acute coronary syndrome.JCI insight · 2025Article
- In-depth proteomic profiling identifies potentiation of the LPS response by 7-ketocholesterol.Journal of molecular and cellular cardiology plus · 2025Article
- Fish Oil Supplementation Modifies the Proteome, Lipidome, and Function of High-Density Lipoprotein: Findings from a Trial in Young Healthy Adults.The Journal of nutrition · 2024Article
- Clot or Not? Reviewing the Reciprocal Regulation Between Lipids and Blood Clotting.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Cerebrospinal Fluid Proteomic Profiles in Patients with Postherpetic Neuralgia.Journal of proteome research · 2023Article
- Proteomic Determinants of Variation in Cholesterol Efflux: Observations from the Dallas Heart Study.International journal of molecular sciences · 2023Article
- Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.Journal of thrombosis and haemostasis : JTH · 2023Review
- Development and validation of novel automatable assay for cholesterol efflux capacity.Bioscience reports · 2023Article
- Correlations between the NMR Lipoprotein Profile,International journal of molecular sciences · 2023Article
- A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research.Scientific reports · 2022Article
- Effects of pre-eclampsia on HDL-mediated cholesterol efflux capacity after pregnancy.Atherosclerosis plus · 2022Article
- Plasminogen Deficiency Significantly Reduces Vascular Wall Disease in a Murine Model of Type IIa Hypercholesterolemia.Biomedicines · 2021Article
- Molecular Patterns of Extreme and Persistent Cholesterol Efflux Capacity.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- ADAM17 Boosts Cholesterol Efflux and Downstream Effects of High-Density Lipoprotein on Inflammatory Pathways in Macrophages.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
Using genetic and biochemical approaches, we investigated proteins that regulate macrophage cholesterol efflux capacity (CEC) and ABCA1-specific CEC (ABCA1 CEC), 2 functional assays that predict cardiovascular disease (CVD). Macrophage CEC and the concentration of HDL particles were markedly reduced in mice deficient in apolipoprotein A-I (APOA1) or apolipoprotein E (APOE) but not apolipoprotein A-IV (APOA4). ABCA1 CEC was markedly reduced in APOA1-deficient mice but was barely affected in mice deficient in APOE or APOA4. High-resolution size-exclusion chromatography of plasma produced 2 major peaks of ABCA1 CEC activity. The early-eluting peak, which coeluted with HDL, was markedly reduced in APOA1- or APOE-deficient mice. The late-eluting peak was modestly reduced in APOA1-deficient mice but little affected in APOE- or APOA4-deficient mice. Ion-exchange chromatography and shotgun proteomics suggested that plasminogen (PLG) accounted for a substantial fraction of the ABCA1 CEC activity in the peak not associated with HDL. Human PLG promoted cholesterol efflux by the ABCA1 pathway, and PLG-dependent efflux was inhibited by lipoprotein(a) [Lp(a)]. Our observations identify APOA1, APOE, and PLG as key determinants of CEC. Because PLG and Lp(a) associate with human CVD risk, interplay among the proteins might affect atherosclerosis by regulating cholesterol efflux from macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.